Anemia of renal disease. What it is, what to do and what's new

Journal of Feline Medicine and Surgery

Volumn 13, Issue 9, 2011, Pages 629-640

  Chalhoub, Serge ^a   Langston, Cathy E ^b   Eatroff, Adam ^b  

^a Charleston Veterinary Referral Center   (United States)

^b ANIMAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ANEMIA; ANIMAL; ANIMAL DISEASE; CASE REPORT; CAT; CAT DISEASE; CHRONIC KIDNEY FAILURE; DIFFERENTIAL DIAGNOSIS; DRUG ADMINISTRATION; MALE; REVIEW;

ANEMIA; ANIMALS; CAT DISEASES; CATS; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; HEMATINICS; KIDNEY FAILURE, CHRONIC; MALE; RECOMBINANT PROTEINS;

FELIDAE;

EID: 80052182117     PISSN: 1098612X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfms.2011.07.016     Document Type: Review

References (97)

1. Lulich J.P., Osborne C.A., O'Brien T.D., Polzin D.J. Feline renal failure: questions, answers, questions. Compend Contin Educ Pract Vet 1992, 14:127-153.
2. Jepson R.E., Brodbelt D., Vallance C., Syme H.M., Elliott J. Evaluation of predictors of the development of azotemia in cats. J Vet Intern Med 2009, 23:806-813.
3. Elliott J., Barber P.J. Feline chronic renal failure: clinical findings in 80 cases diagnosed between 1992 and 1995. J Small Anim Pract 1998, 39:78-85.
4. DiBartola S.P., Rutgers H.C., Zack P.M., Tarr M.J. Clinicopathologic findings associated with chronic renal disease in cats: 74 cases (1973-1984). J Am Vet Med Assoc 1987, 190:1196-1202.
5. Cowgill L.D. Pathophysiology and management of anemia in chronic progressive renal failure. Semin Vet Med Surg (Small Anim) 1992, 7:175-182.
6. King J., Tasker S., Gunn-Moore D., Strehlau G., Group B.S. Prognostic factors in cats with chronic kidney disease. J Vet Intern Med 2007, 21:906-916.
7. Boyd L.M., Langston C.E., Thompson K., Zivin K., Imanishi M. Survival in cats with naturally occurring chronic kidney disease (2000-2002). J Vet Intern Med 2008, 22:1111-1117.
8. Maiese K., Chong Z.Z., Shang Y.C. Raves and risks of erythropoietin. Cytokine Growth Factor Rev 2008, 19:145-155.
9. Erslev A.J., Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 1997, 51:622-630.
10. Eschbach J.W., Adamson J.W. Anemia of end-stage renal disease (ESRD). Kidney Int 1985, 28:1-5.
11. Eschbach J.W. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989, 35:134-148.
12. Semenza G.L., Agani F., Booth G., et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 1997, 51:553-555.
13. Semenza G. Regulation of erythropoietin production: new insights into molecular mechanism of oxygen homeostasis. Hematol Oncol Clin North Am 1994, 8:863-864.
14. Zhu H., Bunn H.F. Oxygen sensing and signaling: impact on the regulation of physiologically important genes. Respir Physiol 1999, 115:239-247.
15. Fisher J.W. Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003, 228:1-14.
16. Brazier J., Cooper N., Maloney J.V., Buckberg G. The adequacy of myocardial oxygen delivery in acute normovolemic anemia. Surgery 1974, 75:508-516.
17. Cain S.M. Oxygen delivery and uptake in dogs during anemic and hypoxic hypoxia. J Appl Physiol 1977, 42:228-234.
18. Fishbane S.B., Barry M. Hematologic aspects of kidney disease. Brenner & Rector's the kidney 2008, 1733-1744. Saunders Elsevier, Philadelphia. 8th edn. B.M. Brenner (Ed.).
19. Wilson H.E., Jasani S., Wagner T.B., et al. Signs of left heart volume overload in severely anaemic cats. J Feline Med Surg 2010, 12:904-909.
20. Randolph J.F., Scarlett J.M., Stokol T., MacLeod J.N. Clinical efficacy and safety of recombinant canine erythropoietin in dogs with anemia of chronic renal failure and dogs with recombinant human erythropoietin-induced red cell aplasia. J Vet Intern Med 2004, 18:81-91.
21. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 2001, 16(suppl 7):36-40.
22. Nemeth E., Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009, 122:78-86.
23. Nemeth E., Rivera S., Gabayan V., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004, 113:1271-1276.
24. Young B., Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol 2009, 4:1384-1387.
25. Weiss G., Goodnough L.T. Anemia of chronic disease. N Engl J Med 2005, 352:1011-1023.
26. Brunati C., Cappellini M.D., De Feo T., et al. Uremic inhibitors of erythropoiesis: a study during treatment with recombinant human erythropoietin. Am J Nephrol 1992, 12:9-13.
27. Radtke H.W., Rege A.B., LaMarche M.B., et al. Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J Clin Invest 1981, 67:1623-1629.
28. Kwack C., Balakrishnan V.S. Managing erythropoietin hyporesponsiveness. Semin Dial 2006, 19:146-151.
29. Kanbay M., Perazella M.A., Kasapoglu B., Koroglu M., Covic A. Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management. Blood Purif 2010, 29:1-12.
30. Segev G., Bandt C., Francey T., Cowgill L.D. Aluminum toxicity following administration of aluminum-based phosphate binders in two dogs with renal failure. J Vet Intern Med 2008, 22:1432-1435.
31. Priyadarshi A., Shapiro J.I. Erythropoietin resistance in the treatment of the anemia of chronic renal failure. Semin Dial 2006, 19:273-278.
32. Jeffery E.H., Abreo K., Burgess E., Cannata J., Greger J.L. Systemic aluminum toxicity: effects on bone, hematopoietic tissue, and kidney. J Toxicol Environ Health 1996, 48:649-665.
33. Cannata-Andia J.B., Fernandez-Martin J.L. The clinical impact of aluminium overload in renal failure. Nephrol Dial Transplant 2002, 17(suppl 2):9-12.
34. Erslev A.J., Besarab A. The rate and control of baseline red cell production in hematologically stable patients with uremia. J Lab Clin Med 1995, 126:283-286.
35. Naets J.P. Hematologic disorders in renal failure. Nephron 1975, 14:181-194.
36. Bonomini M., Sirolli V. Uremic toxicity and anemia. J Nephrol 2003, 16:21-28.
37. Miguel A., Miguel A., Linares M., et al. Evidence of an increased susceptibility to lipid peroxidation in red blood cells of chronic renal failure patients. Nephron 1988, 50:64-65.
38. Linthorst G.E., Avis H.J., Levi M. Uremic thrombocytopathy is not about urea. J Am Soc Nephrol 2010, 21:753-755.
39. Boccardo P., Remuzzi G., Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004, 30:579-589.
40. Boyle J.M., Johnston B. Acute upper gastrointestinal hemorrhage in patients with chronic renal disease. Am J Med 1983, 75:409-412.
41. Himmelfarb J. Hematologic manifestations of renal failure. Primer on kidney diseases 2005, 519-526. Elsevier Saunders, Philadelphia. 4th edn. A. Greenberg (Ed.).
42. Rosenblatt S.G., Drake S., Fadem S., Welch R., Lifschitz M.D. Gastrointestinal blood loss in patients with chronic renal failure. Am J Kidney Dis 1982, 1:232-236.
43. Karagiannis S., Goulas S., Kosmadakis G., et al. Wireless capsule endoscopy in the investigation of patients with chronic renal failure and obscure gastrointestinal bleeding (preliminary data). World J Gastroenterol 2006, 12:5182-5185.
44. Stolic R.V., Jovanovic A.N., Zivic Z.P., et al. Influence of the level of renal insufficiency on endoscopic changes in the upper gastrointestinal tract. Am J Med Sci 2008, 336:39-43.
45. Abu Farsakh N.A., Roweily E., Rababaa M., Butchoun R. Brief report: evaluation of the upper gastrointestinal tract in uraemic patients undergoing haemodialysis. Nephrol Dial Transplant 1996, 11:847-850.
46. Shirazian S., Radhakrishnan J. Gastrointestinal disorders and renal failure: exploring the connection. Nat Rev Nephrol 2010, 6:480-492.
47. Goldstein R.E., Marks S.L., Kass P.H., Cowgill L.D. Gastrin concentrations in plasma of cats with chronic renal failure. J Am Vet Med Assoc 1998, 213:826-828.
48. Ciccotosto G.D., Dawborn J.K., Hardy K.J., Shulkes A. Gastrin processing and secretion in patients with end-stage renal failure. J Clin Endocrinol Metab 1996, 81:3231-3238.
49. Kes P. Serum gastrin concentration in chronic renal failure. Acta Med Croatica 1992, 46:47-58.
50. Peters R.M., Goldstein R.E., Erb H.N., Njaa B.L. Histopathologic features of canine uremic gastropathy: a retrospective study. J Vet Intern Med 2005, 19:315-320.
51. Car B. Erythropoiesis and erythrokinetics. Schalm's veterinary hematology 2000, 105-109. Lippincott, Williams & Wilkins, Philadelphia. 5th edn. B.F. Feldman, J.G. Zinkl, N.C. Jain (Eds.).
52. Bunn H. Erythropoietin: current status. Yale J Biol Med 1990, 63:381-386.
53. Jelkman W. Molecular biology of erythropoietin. Intern Med 2004, 43:649-659.
54. Porter D., Goldberg M. Physiology of erythropoietin production. Semin Hematol 1994, 31:112-121.
55. Egrie J.C., Strickland T.W., Lane J., et al. Characterization and biological effects of recombinant human erythropoietin. Immunobiology 1986, 172:213-224.
56. Storring P.L., Tiplady R.J., Gaines Das R.E., et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998, 100:79-89.
57. Langston C.E., Reine N.J., Kittrell D. The use of erythropoietin. Vet Clin North Am Small Animal Pract 2003, 33:1245-1260.
58. MacLeod JN. Species-specific recombinant erythropoietin preparations for companion animals. In: Proceedings of 2001 ACVIM Veterinary Medical Forum; 2001; Denver, CO: 578-579.
59. MacLeod J.N., Tetreault J.W., Lorschy K.A.S., Gu D.N. Expression and bioactivity of recombinant canine erythropoietin. Am J Vet Res 1998, 59:1144-1148.
60. Egrie J.C., Dwyer E., Browne J.K., Hitz A., Lykos M.A. Darbepoetin alfa has a longer circulation half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003, 31:290-299.
61. Macdougall I.C., Matcham J., Gray S. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant 2003, 18:576-581.
62. Macdougall I.C. Darbepoetin alfa: a new therapeutic agent for renal anemia. Kidney Int 2002, 61(suppl 80):S55-S61.
63. Harris D., Collins J., Disney A., et al. Darbepoetin alfa: a new erythropoietic drug for the treatment of renal anaemia. Nephrol 2002, 7. S173-SS80.
64. Brunkhorst R., Bommer J., Braun J., et al. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 2004, 19:1224-1230.
65. Locatelli F., Canaud B., Giacardy F., Martin-Malo A., Baker N., Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003, 18:362-369.
66. Toto R.D., Pichette V., Navarro J., et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004, 24:453-460.
67. Carrera F., Oliveira L., Maia P., Mendes T., Ferreira C. The efficacy of intravenous darbepoetin alfa adminstered once every 2 weeks in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant 2006, 21:2846-2850.
68. Macdougall I.C. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 2008, 3:200-207.
69. Randolph J.F., Scarlett J.M., Stokol T., Saunders K.M., MacLeod J.N. Expression, bioactivity, and clinical assessment of recombinant feline erythropoietin. Am J Vet Res 2004, 65:1355-1366.
70. Macdougall I.C. Strategies for iron supplementation: oral versus intravenous. Kidney Int 1999, 55(suppl 69). S61-SS6.
71. Schiesser D., Binet I., Tsinalis D., et al. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requriement in iron-replete haemodialysis patients. Nephrol Dial Transplant 2006, 21:2841-2845.
72. Sjaastad O.V., Framstad T., Blom A.K. Effect of iron on erythropoietin production in anaemic piglets. Acta Vet Scand 1996, 37:133-138.
73. Fishbane S., Masani N. Anemia in chronic kidney disease. Chronic kidney disease, dialysis, and transplantation 2005, 122-135. Elsevier Saunders, Philadelphia. 2nd edn. B.J.G. Pereira, M.H. Sayegh, P. Blake (Eds.).
74. Shahani S., Braga-Basaria M., Maggio M., Basaria S. Androgens and erythropoiesis: past and present. J Endocrinol Invest 2009, 32:704-716.
75. Johansen K.L. The role of nandrolone decanoate in patients with end stage renal disease in the erythropoietin era. Int J Artif Organs 2001, 24:183-185.
76. Dainiak N. The role of androgens in the treatment of anemia of chronic renal failure. Semin Nephrol 1985, 5:147-154.
77. Basaria S., Wahlstrom J.T., Dobs A.S. Clinical review 138: anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab 2001, 86:5108-5117.
78. Harkin K.R., Cowan L.A., Andrews G.A., et al. Hepatotoxicity of stanozolol in cats. J Am Vet Med Assoc 2000, 217:681-684.
79. Callan M.B., Rentko V.T. Clinical application of a hemoglobin-based oxygen-carrying solution. Vet Clin North Am Small Anim Pract 2003, 33:1277-1293. vi.
80. Weingart C., Kohn B. Clinical use of a haemoglobin-based oxygen carrying solution (Oxyglobin) in 48 cats (2002-2006). J Feline Med Surg 2008, 10:431-438.
81. Don T., Friedlander S., Wong W. Dietary intakes and biochemical status of B vitamins in a group of children receiving dialysis. J Ren Nutr 2010, 20:23-28.
82. Druml W. Nutritional support in patients with acute renal failure. Acute renal failure: a companion to Brenner and Rector's the kidney 2001, 465-489. WB Saunders, Philadelphia. B.A. Molitoris, W.F. Finn (Eds.).
83. Fouque D., Holt S., Guebre-Egziabher F., et al. Relationship between serum carnitine, acylcarnitines, and renal function in patients with chronic renal disease. J Ren Nutr 2006, 16:125-131.
84. Stivelman J.C., Fishbane S., Nissenson A.R. Erythropoietin therapy in renal disease and renal failure. Brenner & Rector's the kidney 2008, 1884-1903. Saunders Elsevier, Philadelphia. 8th edn. B.M. Brenner (Ed.).
85. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002, 16:87-96.
86. Cowgill L.D., James K.M., Levy J.K., et al. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure. J Am Vet Med Assoc 1998, 212:521-528.
87. Pollock C., Johnson D.W., Horl W.H., et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2008, 3:193-199.
88. Macdougall I.C. An overview of the efficacy and safety of novel erythropoiesis stimulating protien (NESP). Nephrol Dial Transplant 2001, 16(suppl 3):14-21.
89. Macdougall I.C. Antibody-mediated pure red cell aplasia (PCRA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant 2005, 20(suppl 4):iv9-iv15.
90. Wen D., Boissel J.P., Tracy T.E., et al. Erythropoietin structure-function relationships: high degree of sequence homology among mammals. Blood 1993, 82:1507-1516.
91. Cowgill L.D. Application of recombinant human erythropoietin in dogs and cats. Current veterinary therapy XI 1992, 484-487. WB Saunders, Philadelphia. R.W. Kirk, J.D. Bonagura (Eds.).
92. Bennett C.L., Cournoyer D., Carson K.R., et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005, 106:3343-3347.
93. Rossert J., Macdougall I.C., Casadevall N. Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options. Nephrol Dial Transplant 2005, 20(suppl 4). iv23-iv6.
94. Steinberg J.D., Olver C.S. Hematologic and biochemical abnormalities indicating iron deficiency are associated with decreased reticulocyte hemoglobin content (CHr) and reticulocyte volume (rMCV) in dogs. Vet Clin Pathol 2005, 34:23-27.
95. Bernhardt W.M., Wiesener M.S., Scigalla P., et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010, 21:2151-2156.
96. Owen W.E., Roberts W.L. Performance characteristics of a new Immulite 2000 system erythropoietin assay. Clin Chim Acta 2011, 412:480-482.
97. Schwarz P., Strnad P., von Figura G., et al. A novel monoclonal antibody immunoassay for the detection of human serum hepcidin. J Gastroenterol 2011, 46:648-656.